Loading...
•
Dec 31, 2025
Pacific Biosciences Q4 2025 Earnings Report
Pacific Biosciences reported higher fourth quarter 2025 revenue with improved gross margins, while posting a GAAP net loss.
Key Takeaways
For Q4 2025, PacBio generated total revenue of 44645000, up year-over-year, with GAAP net loss of 40371000 and gross profit of 16566000. Non-GAAP gross margin improved to 40% compared to 31% in the prior year quarter.
Revenue increased to 44645000 from 39224000 year-over-year.
Consumables revenue reached 21600000, up from 18800000.
GAAP gross profit was 16566000 with 37% gross margin.
Revio placements were 21 and Vega placements were 42 during the quarter.
Revenue by Segment
Forward Guidance
Management highlighted strengthened balance sheet following the sale of short-read assets and expects growth acceleration with the upcoming SPRQ-Nx launch aimed at lowering sequencing costs.
Positive Outlook
- Strengthened balance sheet after $48100000 net cash proceeds from asset sale.
- Record consumables revenue in Q4 2025.
- Non-GAAP gross margin improved to 40%.
- Growing clinical market adoption.
- Upcoming SPRQ-Nx launch designed to lower sequencing costs.
Challenges Ahead
- GAAP net loss of 40371000 in Q4 2025.
- Operating loss of 41197000.
- Ongoing restructuring costs impacting profitability.
- Interest expense of 1740000 in the quarter.
- Macroeconomic uncertainties affecting capital spending.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...